

Jose M Aramendia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5466914/publications.pdf>

Version: 2024-02-01

35
papers

634
citations

759055

12
h-index

580701

25
g-index

39
all docs

39
docs citations

39
times ranked

713
citing authors

#	ARTICLE	IF	CITATIONS
1	Front-Line Paclitaxel/Cisplatin-Based Chemotherapy in Brain Metastases from Non-Small-Cell Lung Cancer. <i>Oncology</i> , 2003, 64, 28-35.	0.9	126
2	Combined Treatment in Superior Sulcus Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1994, 17, 317-322.	0.6	67
3	Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis. Treatment with N-acetylcysteine. <i>British Journal of Dermatology</i> , 1997, 136, 645-646.	1.4	59
4	Intraoperative radiotherapy electron boost followed by moderate doses of external beam radiotherapy in resected soft-tissue sarcoma of the extremities. <i>Radiotherapy and Oncology</i> , 2003, 67, 331-337.	0.3	53
5	Docetaxel Administered During Pregnancy for Inflammatory Breast Carcinoma. <i>Clinical Breast Cancer</i> , 2006, 6, 533-534.	1.1	51
6	Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1396-1405.	3.3	51
7	Determination of Docetaxel and Paclitaxel in Human Plasma by High-Performance Liquid Chromatography. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 199-205.	1.0	36
8	Combined Irinotecan, Oxaliplatin and 5-Fluorouracil in Patients with Advanced Colorectal Cancer. <i>Oncology</i> , 2002, 63, 254-265.	0.9	21
9	Early breast cancer treated with conservative surgery, adjuvant chemotherapy, and delayed accelerated partial breast irradiation with high-dose-rate brachytherapy. <i>Brachytherapy</i> , 2008, 7, 310-315.	0.2	15
10	The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes. <i>British Journal of Cancer</i> , 2021, 124, 1138-1149.	2.9	14
11	Cisplatin, Mitomycin, and Vindesine Followed by Intraoperative and Postoperative Radiotherapy for Stage III Non-Small Cell Lung Cancer: Final Results of a Phase II study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997, 20, 276-281.	0.6	14
12	Second-Line Chemotherapy With Irinotecan and Vinorelbine in Stage IIIB and IV Non-Small-Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 480-484.	0.6	13
13	Phase I and Pharmacokinetic Study of Gemcitabine Administered at Fixed-Dose Rate, Combined with Docetaxel/Melphalan/Carboplatin, with Autologous Hematopoietic Progenitor-Cell Support, in Patients with Advanced Refractory Tumors. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1324-1337.	2.0	12
14	Multicatheter breast implant during breast conservative surgery: Novel approach to deliver accelerated partial breast irradiation. <i>Brachytherapy</i> , 2016, 15, 485-494.	0.2	12
15	Induction Platinum-Based Chemotherapy Followed by Radical Hyperfractionated Radiotherapy With Concurrent Chemotherapy in the Treatment of Locally Advanced Non-Small-Cell Carcinoma of the Lung. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1999, 22, 203-208.	0.6	12
16	Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile. <i>Current Cancer Drug Targets</i> , 2016, 16, 415-428.	0.8	10
17	A Phase II Trial of Less Than 7 Weeks of Concomitant Cisplatin-Paclitaxel Chemoradiation in Locally Advanced Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 133-140.	1.2	9
18	Neurological and cytological response as potential early predictors of time-to-progression and overall survival in patients with leptomeningeal carcinomatosis treated with intrathecal liposomal cytarabine: a retrospective cohort study. <i>Journal of Neuro-Oncology</i> , 2013, 115, 429-435.	1.4	9

#	ARTICLE	IF	CITATIONS
19	Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience. <i>Breast Journal</i> , 2018, 24, 473-479.	0.4	9
20	Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 457-465.	1.1	5
21	A novel BRCA2 mutation that segregates with breast and prostate cancer in a Spanish family. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 219-220.	1.1	5
22	Utility of delayed reading of intradermal test in carboplatin-induced drug hypersensitivity. <i>Annals of Allergy, Asthma and Immunology</i> , 2015, 114, 534-535.	0.5	5
23	Paclitaxel, Cisplatin, and Vinorelbine Combination Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 299-303.	0.6	4
24	Intraoperative electron beam radiotherapy and perioperative high-dose-rate brachytherapy in previously irradiated oligorecurrent gynecological cancer: clinical outcome analysis. <i>Clinical and Translational Oncology</i> , 2021, 23, 1934-1941.	1.2	4
25	A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy. <i>Cancers</i> , 2022, 14, 2941.	1.7	4
26	Radiation Therapy After High-Dose Chemotherapy With Peripheral Blood Stem Cell Support for High-Risk Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 347-353.	0.6	3
27	Perioperative high-dose-rate brachytherapy in locally advanced and recurrent gynecological cancer: Final results of a Phase II trial. <i>Brachytherapy</i> , 2018, 17, 734-741.	0.2	3
28	Long-Term Results of a Phase II Trial of Concomitant Cisplatin-Paclitaxel Chemoradiation in Locally Advanced Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1162-1168.	1.2	2
29	The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2020, 41, 523.	0.3	1
30	Impact of CD8 stromal lymphocytes in BC patients with the addition of autologous dendritic CELL vaccination to neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1081-1081.	0.8	1
31	A single prior course of BCNU-cisplatin chemotherapy has a significant deleterious effect on mobilization kinetics of otherwise untreated patients. <i>Bone Marrow Transplantation</i> , 2004, 33, 499-502.	1.3	0
32	A novel mutation in BRCA1 linked to breast and ovarian cancer and a genotype-phenotype correlation. <i>Oncology Letters</i> , 2011, 2, 807-809.	0.8	0
33	Bevacizumab plus irinotecan in patients with recurrent high grade malignant gliomas.. <i>Journal of Clinical Oncology</i> , 2015, 33, e13057-e13057.	0.8	0
34	Neoadjuvant chemotherapy based on dose-dense epirubicin (E) plus cyclophosphamide (C) followed by docetaxel (D) plus trastuzumab (T), DT plus carboplatin (CBDCA), or DT plus HER2 double blockade in HER2-positive breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11617-e11617.	0.8	0
35	A population model to predict progression free survival in breast cancer patients treated with neoadjuvant chemotherapy ± vaccines based on tumour growth inhibition metrics.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12114-e12114.	0.8	0